Evolva Holding AI Stock Analysis
Want to see CH:EVE full AI Analyst Report?
Evolva Holding (EVE) AI Stock Analysis
Evolva Holding
(Six Swiss:EVE)
The overall score is severely constrained by the company's dire financial fundamentals, including zero revenue and ongoing losses, which present an existential risk. Positive technical momentum provides a partial offset, indicating some short-term market optimism, but this is a secondary factor. The negative P/E ratio further confirms the lack of fundamental value, resulting in a low overall assessment.
Evolva Holding (EVE) vs. iShares MSCI Switzerland ETF (EWL)
- Market Cap
- CHF 15.50M
- Dividend Yield
- ―
- Average Volume (3M)
- 41.53K
- Price to Earnings (P/E)
- -17.7
- Beta (1Y)
- 0.42
- Revenue Growth
- ―
- EPS Growth
- -39.83%
- Country
- Switzerland
- Employees
- 49
- Sector
- Financial
- Sector Strength
- 68
- Industry
- Shell Companies
Evolva Holding Business Overview & Revenue Model
Company Description
EvoNext Holdings SA is dedicated to the exploration, creation, and distribution of pioneering ingredients across the nutritional, health, and wellness domains. Founded in 2004, the company's inception is attributed to Alexandra Santana Sørensen, Søre...
Evolva Holding Financial Statement Overview
Summary
Financial health is critically weak. Revenue has collapsed to zero, the income statement is deeply unprofitable, and the equity base is minimal. While the balance sheet is debt-free and cash burn has slowed, the lack of any viable business model or revenue stream makes this the most significant risk factor.
Income Statement
12Very NegativeBalance Sheet
30NegativeCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 9.44M | 15.54M | 9.88M |
| Gross Profit | 0 | 0 | 0 | -4.83M | -8.89M | -9.31M |
| EBITDA | -775.00K | -652.10K | 3.96M | -98.36M | -34.52M | -31.82M |
| Net Income | -926.70K | -652.70K | 1.04M | -105.23M | -43.37M | -41.27M |
Balance Sheet | ||||||
| Total Assets | 5.57M | 6.76M | 7.54M | 9.83M | 131.01M | 156.17M |
| Cash, Cash Equivalents and Short-Term Investments | 4.22M | 5.61M | 6.75M | 5.84M | 5.14M | 11.00M |
| Total Debt | 0 | 0 | 0 | 0 | 15.06M | 10.84M |
| Total Liabilities | 264.10K | 812.70K | 945.30K | 4.28M | 24.77M | 24.40M |
| Stockholders Equity | 5.31M | 5.94M | 6.60M | 5.55M | 106.24M | 131.77M |
Cash Flow | ||||||
| Free Cash Flow | -2.10M | 0 | -2.44M | -9.72M | -21.13M | -33.57M |
| Operating Cash Flow | -2.10M | -1.14M | -2.44M | -9.25M | -18.88M | -29.79M |
| Investing Cash Flow | 0 | 0 | 3.52M | 15.95M | -1.76M | -4.64M |
| Financing Cash Flow | 0 | 0 | -163.10K | -5.97M | 14.77M | 25.72M |
Evolva Holding Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:EVE, the sentiment is Neutral. The current price of 2.28 is below the 20-day moving average (MA) of 2.33, above the 50-day MA of 2.25, and above the 200-day MA of 1.68, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 46.70 is Neutral, neither overbought nor oversold. The STOCH value of 34.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:EVE.
Evolva Holding Peers Comparison
Overall Rating
CH:BANB80Outperform
CH:LONN67Neutral
CH:KURN66Neutral
CH:EVE45Neutral
CH:MOLN38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | CHF 5.97B | 39.97 | 10.27% | 1.13% | 4.51% | 11.05% | |
| Sector * | 68Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
| 67Neutral | CHF 45.39B | 41.81 | ― | 0.75% | -10.77% | -114.77% | |
| 66Neutral | CHF 775.42M | 107.57 | 10.24% | ― | 40.91% | ― | |
| 45Neutral | CHF 16.45M | -17.74 | -16.47% | ― | ― | -39.83% | |
| 38Underperform | CHF 96.90M | -1.78 | -79.25% | ― | ― | 16.86% |
* Financial Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CH:EVE | Evolva Holding Sa | 2.28 | 1.43 | 168.24% | |
| CH:MOLN | Molecular Partners | 2.40 | -0.91 | -27.38% | |
| CH:LONN | Lonza Group | 666.00 | 142.29 | 27.17% | |
| CH:BANB | Bachem Holding AG Class B | 79.55 | 31.45 | 65.38% | |
| CH:KURN | Kuros Biosciences | 19.47 | -7.41 | -27.57% | |
| CH:XLS | Xlife Sciences Ltd. | 8.48 | -8.12 | -48.92% |
Evolva Holding Corporate Events
Ascend to Go Public via EvoNext Merger in CHF 500m Sports Tech Deal
EvoNext Holdings SA and Ascend Sport Technology AG have agreed to merge in a statutory transaction that will take Ascend public via EvoNext’s existing listing on SIX Swiss Exchange, creating a listed Swiss sports technology company with global reach....
EvoNext Posts Modest Loss as Talks Advance on Reverse Merger with Ascend Sport Technology
EvoNext Holdings SA reported liquidity of CHF 5.5 million and equity of CHF 5.3 million as of 30 June 2026, with a net loss of CHF 0.6 million driven mainly by one-off transaction and search-related costs. The company’s half-year figures highlight a...
EvoNext in advanced talks on reverse merger with AI sports tech firm Ascend
EvoNext Holdings SA has confirmed it is in advanced talks with Ascend Sport Technology AG over a reverse merger that would bring the profitable, AI-driven Swiss sports technology firm to the SIX Swiss Exchange. The contemplated deal envisages valuing...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 13, 2026
